An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models

被引：0
|
作者：
Hu, S. [1 ]
Marineau, J. [1 ]
Bradley, M. [1 ]
Hamman, K. [1 ]
Alnemy, S. [1 ]
Smith, D. [1 ]
Carulli, J. [1 ]
Chuaqui, C. [1 ]
机构：
[1] Syros Pharmaceut Inc, Drug Discovery, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96 (PB-047
引用
收藏
页码：E39 / E40
页数：2
相关论文
共 50 条
  • [31] Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models
    Arango, Natalia Paez
    Evans, Kurt
    Zhao, Ming
    Yuca, Erkan
    Scott, Stephen
    Kim, Charissa
    Naing, Aung
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2016, 76
  • [32] A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
    Howell, Sacha J.
    Kenny, Laura M.
    Lord, Simon
    Krebs, Matthew G.
    Arkenau, Tobias
    Baird, Richard
    MacPherson, Iain R.
    Bahl, Ash
    Clack, Glen
    Ainscow, Edward
    Barrett, Anthony G. M.
    Dickinson, Paul A.
    Fuchter, Matthew J.
    Lehnert, Manfred
    Ali, Simak
    McIntosh, Stuart
    Coombes, Charles
    CANCER RESEARCH, 2022, 82 (04)
  • [33] N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer
    Zhang, Limei
    Wu, Lihong
    Zhou, Duanfang
    Wang, Gang
    Chen, Bo
    Shen, Zhengze
    Li, Xiaoli
    Wu, Qiuya
    Qu, Na
    Wu, Yuanli
    Yuan, Lie
    Gan, Zongjie
    Zhou, Weiying
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 955
  • [34] The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer
    Greenaway, James B.
    Koehler, Anne
    McCulloch, Christopher A.
    Petrik, James
    Brown, Theodore J.
    Ringuette, Maurice J.
    BIOCHEMISTRY AND CELL BIOLOGY, 2012, 90 (01) : 96 - 107
  • [35] Selective in vitro and in vivo anti-tumor activity of PRLX 93936 in biological models of melanoma and ovarian cancer
    Sahasrabudhe, S. R.
    Lai, S.
    Pierce, M.
    Clemens, C.
    Venkat, R.
    Rebentisch, M.
    Senina, A.
    Becklin, R.
    Richards, S. K.
    Erkkila, T.
    Robbins, P. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] MLN8054, an Aurora A Kinase inhibitor, demonstrates potent anti-tumor activity in disseminated tumor models
    Zhang, M.
    Meetze, M.
    Huck, J.
    Silva, M.
    Sells, T.
    Claiborne, C.
    Manfredi, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 113 - 113
  • [37] SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models
    Johannessen, Liv
    Henry, Susan
    Sawant, Priyanka
    D'Ippolito, Anthony
    Ke, Nan
    Lefkowitz, Ariel
    Eaton, Matthew
    Dworakowski, Wojciech
    Rosario, Maria
    Hodgson, Graeme
    BLOOD, 2021, 138
  • [38] Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
    Natalia Paez Arango
    Erkan Yuca
    Ming Zhao
    Kurt W. Evans
    Stephen Scott
    Charissa Kim
    Ana Maria Gonzalez-Angulo
    Filip Janku
    Naoto T. Ueno
    Debu Tripathy
    Argun Akcakanat
    Aung Naing
    Funda Meric-Bernstam
    Breast Cancer Research, 19
  • [39] Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
    Arango, Natalia Paez
    Yuca, Erkan
    Zhao, Ming
    Evans, Kurt W.
    Scott, Stephen
    Kim, Charissa
    Gonzalez-Angulo, Ana Maria
    Janku, Filip
    Ueno, Naoto T.
    Tripathy, Debu
    Akcakanat, Argun
    Naing, Aung
    Meric-Bernstam, Funda
    BREAST CANCER RESEARCH, 2017, 19
  • [40] Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers.
    Zhou, Feng
    Yang, Guimei
    Tang, Feng
    Zhang, Yan
    Yang, Wenqing
    Xue, Liting
    Chen, Ping
    Tang, Renhong
    CANCER RESEARCH, 2022, 82 (12)
12345